DK1559427T3 - Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel - Google Patents

Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel

Info

Publication number: DK1559427T3
Authority: DK; Denmark
Prior art keywords: bladder; rat; drug; active ingredient; overactive bladder
Prior art date: 2002-11-07

Application number

DK03770134.9T

Other languages

English (en)

Inventor

Shuichi Sato

Masashi Ukai

Tatsuya Maruyama

Toshiyuki Takasu

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-07

Filing date

2003-11-04

Publication date

2011-04-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1559427(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-04 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2011-04-26 Application granted granted Critical

2011-04-26 Publication of DK1559427T3 publication Critical patent/DK1559427T3/da

Links

206010020853 Hypertonic bladder Diseases 0.000 title abstract 2
208000009722 Overactive Urinary Bladder Diseases 0.000 title abstract 2
208000020629 overactive bladder Diseases 0.000 title abstract 2
FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical class CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 title 1
239000004480 active ingredient Substances 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
230000008602 contraction Effects 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 2
238000005259 measurement Methods 0.000 abstract 2
230000027939 micturition Effects 0.000 abstract 2
230000001020 rhythmical effect Effects 0.000 abstract 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000003931 anilides Chemical class 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229960004397 cyclophosphamide Drugs 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000004648 relaxation of smooth muscle Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK03770134.9T 2002-11-07 2003-11-04 Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel DK1559427T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002323792		2002-11-07
PCT/JP2003/014065 WO2004041276A1 (ja)	2002-11-07	2003-11-04	酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤

Publications (1)

Publication Number	Publication Date
DK1559427T3 true DK1559427T3 (da)	2011-04-26

Family

ID=32310425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03770134.9T DK1559427T3 (da)	2002-11-07	2003-11-04	Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel

Country Status (28)

Country	Link
US (5)	US7750029B2 (da)
EP (1)	EP1559427B1 (da)
JP (1)	JP3815496B2 (da)
KR (1)	KR100967070B1 (da)
CN (1)	CN100406011C (da)
AT (1)	ATE500827T1 (da)
AU (1)	AU2003284700B2 (da)
BE (1)	BE2013C040I2 (da)
BR (1)	BR0316080A (da)
CA (1)	CA2503570C (da)
CY (2)	CY1111399T1 (da)
DE (1)	DE60336334D1 (da)
DK (1)	DK1559427T3 (da)
ES (1)	ES2360353T3 (da)
FR (1)	FR13C0032I2 (da)
HU (1)	HUS1300027I1 (da)
IL (1)	IL168121A (da)
LU (1)	LU92218I2 (da)
MX (1)	MXPA05004925A (da)
NL (1)	NL300599I2 (da)
NO (2)	NO334948B1 (da)
NZ (1)	NZ539577A (da)
PL (1)	PL211687B1 (da)
PT (1)	PT1559427E (da)
RU (1)	RU2321401C2 (da)
SI (1)	SI1559427T1 (da)
WO (1)	WO2004041276A1 (da)
ZA (1)	ZA200503510B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10351271A1 (de) *	2003-10-31	2005-06-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
CA2704298C (en)	2007-11-02	2015-07-21	Astellas Pharma Inc.	Pharmaceutical composition for treating overactive bladder
EP2223690A4 (en) *	2007-12-21	2011-02-23	Astellas Pharma Inc	PHARMACEUTICAL COMPOSITION USED TO MITIGATE SYMPTOMS OF THE INFINITE URINARY TRACT
PE20091825A1 (es) *	2008-04-04	2009-12-04	Merck & Co Inc	Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh) *	2008-09-30	2015-04-01	Astellas Pharma Inc	釋控性醫藥組成物
WO2010053068A1 (ja) *	2008-11-07	2010-05-14	大日本住友製薬株式会社	新規で有用な下部尿路症状治療剤
US8586760B2 (en) *	2009-06-15	2013-11-19	Auspex Pharmaceuticals, Inc.	Aminothiazole modulators of beta-3-adrenoreceptor
WO2011122523A1 (ja) *	2010-03-29	2011-10-06	アステラス製薬株式会社	放出制御医薬組成物
ES2665467T3 (es)	2010-03-29	2018-04-25	Astellas Pharma Inc.	Composición farmacéutica de liberación modificada
US9655885B2 (en)	2011-05-18	2017-05-23	Dr. Reddy's Laboratories Ltd.	Amorphous mirabegron and processes for crystal forms of mirabegron
IN2013CN09704A (da)	2011-05-18	2015-07-03	Reddys Lab Ltd Dr
EP2832730A4 (en)	2012-03-30	2015-09-09	Astellas Pharma Inc	MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
CA2883270A1 (en)	2012-08-31	2014-03-06	Astellas Pharma Inc.	Orally administered medical composition
WO2014132270A2 (en) *	2013-02-27	2014-09-04	Msn Laboratories Limited	Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (zh) *	2013-04-17	2013-07-10	苏州永健生物医药有限公司	一种米拉贝隆的合成方法
CN103232368B (zh) *	2013-04-18	2015-08-12	苏州永健生物医药有限公司	一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103193658A (zh) *	2013-04-18	2013-07-10	苏州永健生物医药有限公司	一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232352B (zh) *	2013-05-11	2015-12-23	苏州永健生物医药有限公司	(r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CN105579057A (zh) *	2013-07-23	2016-05-11	阿勒根公司	包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
ITMI20131653A1 (it) *	2013-10-07	2015-04-08	Dipharma Francis Srl	Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) *	2013-11-29	2015-05-20	Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации	Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (en) *	2014-04-08	2015-10-15	Suven Life Sciences Limited	An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) *	2014-04-22	2015-10-29	Calyx Chemicals And Pharmaceuticals Ltd.	Novel process for preparation of mirabegron and it's intermediate
CN104016943A (zh) *	2014-05-23	2014-09-03	苏州凯瑞医药科技有限公司	一种米拉贝隆的合成方法
CN104016877B (zh) *	2014-06-13	2017-02-15	南京海融制药有限公司	一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) *	2014-09-05	2014-12-24	安徽联创药物化学有限公司	米拉贝隆的合成方法
JP2017535567A (ja)	2014-11-20	2017-11-30	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
CN104496841B (zh) *	2014-11-26	2017-01-25	南京工业大学	一种米拉贝隆中间体的合成方法
CN104744292A (zh) *	2015-03-11	2015-07-01	南京工业大学	(r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja)	2015-03-31	2018-06-14	アステラス製薬株式会社	ミラベグロン含有医薬組成物
JP6618736B2 (ja)	2015-09-01	2019-12-11	沢井製薬株式会社	ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) *	2016-08-12	2022-07-15	浙江华海药业股份有限公司	一种米拉贝隆中间体的后处理方法
EP3360866B1 (en)	2017-02-14	2019-01-02	Alfred E. Tiefenbacher (GmbH & Co. KG)	Mirabegron prodrugs
KR102051132B1 (ko) *	2017-03-17	2019-12-02	주식회사 종근당	미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko)	2017-04-13	2018-06-20	(주) 성운파마코피아	아미드 유도체의 제조방법
US11123320B2 (en)	2017-05-31	2021-09-21	Sbi Pharmaceuticals, Co., Ltd.	Prophylactic or therapeutic agent for hyperaciive bladder
EP3634420A1 (en)	2017-06-06	2020-04-15	Urovant Sciences GmbH	Use of vibegron to treat overactive bladder
KR102398639B1 (ko)	2017-06-20	2022-05-17	(주) 성운파마코피아	아미드 유도체의 염 및 그 제조방법
KR101937713B1 (ko)	2017-07-14	2019-01-14	주식회사 대웅제약	약제학적 제제 및 그 제조방법
WO2019013583A2 (ko)	2017-07-14	2019-01-17	주식회사 대웅제약	약제학적 제제 및 그 제조방법
SG11202103662VA (en)	2018-12-05	2021-06-29	Urovant Sciences Gmbh	Vibegron for the treatment of overactive bladder symptoms
KR20200117091A (ko)	2019-04-02	2020-10-14	제이투에이치바이오텍 (주)	미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (en)	2020-04-08	2022-03-30	Alfred E. Tiefenbacher (GmbH & Co. KG)	Process for preparing mirabegron enacarbil
CN113816864B (zh) *	2020-06-18	2024-03-29	南京正大天晴制药有限公司	一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko)	2020-12-08	2022-06-15	주식회사 한서켐	미라베그론 α형 결정의 제조방법
EP4338729A1 (en)	2022-09-19	2024-03-20	Sanovel Ilac Sanayi Ve Ticaret A.S.	A tablet comprising mirabegron
EP4410279A1 (en)	2023-01-25	2024-08-07	Sanovel Ilac Sanayi Ve Ticaret A.S.	A film tablet comprising mirabegron
KR20240171516A (ko)	2023-05-30	2024-12-09	주식회사 디앤아이바이오	미라베그론 서방정
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release
TR2024008630A1 (tr)	2024-07-04	2026-01-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Mi̇rabegron i̇çeren modi̇fi̇ye salimli bi̇r tablet bi̇leşi̇mi̇
WO2026064392A1 (en)	2024-09-17	2026-03-26	Flavostar Llc	Fixed dose combination of flavoxate and beta-3 adrenergic receptor agonists, and formulations and manufacturing processes thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH07119189B2 (ja)	1989-09-28	1995-12-20	北陸製薬株式会社	光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en)	1991-04-12	1991-05-29	Fujisawa Pharmaceutical Co	New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en)	1992-02-03	1997-03-18	Fujisawa Pharmaceutical Co	Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja)	1993-04-05	1994-10-21	Fujisawa Pharmaceut Co Ltd	β３−アドレナリン作動薬の新規医薬用途
JPH08509491A (ja)	1993-04-26	1996-10-08	藤沢薬品工業株式会社	胃腸疾患の治療に有用なエタノールアミン誘導体
JPH07228543A (ja)	1994-02-16	1995-08-29	Fujisawa Pharmaceut Co Ltd	β３−アドレナリン作動薬の新規医薬用途
WO1997015549A1 (en)	1995-10-26	1997-05-01	Tokyo Tanabe Company Limited	PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME
WO1998000016A1 (en) *	1996-07-01	1998-01-08	Sepracor, Inc.	Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
JP4685201B2 (ja)	1996-08-19	2011-05-18	キッセイ薬品工業株式会社	頻尿および尿失禁の予防・治療剤
EP1014957A4 (en) *	1997-08-28	2004-01-28	Afferon Corp	URINARY INCONTINENCE THERAPY
ATE266639T1 (de)	1997-10-17	2004-05-15	Yamanouchi Pharma Co Ltd	Amidderivate oder deren salze
WO1999031045A1 (en)	1997-12-18	1999-06-24	Kissei Pharmaceutical Co., Ltd.	Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
DE69919860T2 (de) *	1998-04-14	2005-08-25	Kissei Pharmaceutical Co., Ltd., Matsumoto	2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen
MY126489A (en) *	1998-07-08	2006-10-31	Kissei Pharmaceutical	Phenoxyacetic acid derivatives and medicinal compositions containing the same
EP1218536A2 (en) *	1999-02-12	2002-07-03	Genset	Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en)	1999-10-12	2001-05-16	Merck & Co Inc	Amide derivatives as beta 3 agonists
JP2001114736A (ja) *	1999-10-19	2001-04-24	Kissei Pharmaceut Co Ltd	２−アミノプロパノール誘導体
US20030018061A1 (en)	2000-01-28	2003-01-23	Kohei Ogawa	Novel remedies with the use of beta 3 agonist
AUPQ585000A0 (en) *	2000-02-28	2000-03-16	Fujisawa Pharmaceutical Co., Ltd.	Aminoalcohol derivatives
AUPQ841300A0 (en)	2000-06-27	2000-07-20	Fujisawa Pharmaceutical Co., Ltd.	New aminoalcohol derivatives
AR035605A1 (es) *	2000-12-11	2004-06-16	Bayer Corp	Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en)	2001-10-30	2008-03-11	Astellas Pharma Inc.	α-form or β-form crystal of acetanilide derivative
US20080009538A1 (en) *	2005-03-21	2008-01-10	Phil Skolnick	Methods and compositions for the treatment of urinary incontinence

2003
- 2003-11-04 DK DK03770134.9T patent/DK1559427T3/da active
- 2003-11-04 US US10/534,290 patent/US7750029B2/en not_active Ceased
- 2003-11-04 WO PCT/JP2003/014065 patent/WO2004041276A1/ja not_active Ceased
- 2003-11-04 CA CA2503570A patent/CA2503570C/en not_active Expired - Lifetime
- 2003-11-04 NZ NZ539577A patent/NZ539577A/en not_active IP Right Cessation
- 2003-11-04 KR KR1020057008158A patent/KR100967070B1/ko not_active Ceased
- 2003-11-04 US US13/542,308 patent/USRE44872E1/en not_active Expired - Lifetime
- 2003-11-04 SI SI200331996T patent/SI1559427T1/sl unknown
- 2003-11-04 EP EP03770134A patent/EP1559427B1/en not_active Expired - Lifetime
- 2003-11-04 PL PL376771A patent/PL211687B1/pl unknown
- 2003-11-04 ES ES03770134T patent/ES2360353T3/es not_active Expired - Lifetime
- 2003-11-04 US US10/534,290 patent/US20060115540A1/en active Granted
- 2003-11-04 MX MXPA05004925A patent/MXPA05004925A/es active IP Right Grant
- 2003-11-04 CN CNB2003801028894A patent/CN100406011C/zh not_active Ceased
- 2003-11-04 PT PT03770134T patent/PT1559427E/pt unknown
- 2003-11-04 RU RU2005117367/15A patent/RU2321401C2/ru active
- 2003-11-04 BR BR0316080-7A patent/BR0316080A/pt not_active Application Discontinuation
- 2003-11-04 JP JP2004549600A patent/JP3815496B2/ja not_active Expired - Lifetime
- 2003-11-04 ZA ZA200503510A patent/ZA200503510B/en unknown
- 2003-11-04 AU AU2003284700A patent/AU2003284700B2/en not_active Expired
- 2003-11-04 DE DE60336334T patent/DE60336334D1/de not_active Expired - Lifetime
- 2003-11-04 AT AT03770134T patent/ATE500827T1/de active
2005
- 2005-04-19 IL IL168121A patent/IL168121A/en active IP Right Grant
- 2005-06-06 NO NO20052691A patent/NO334948B1/no not_active IP Right Cessation
2008
- 2008-12-12 US US12/333,357 patent/US20090093529A1/en not_active Abandoned
2011
- 2011-04-18 CY CY20111100395T patent/CY1111399T1/el unknown
- 2011-05-27 US US13/117,638 patent/US8835474B2/en not_active Expired - Lifetime
2013
- 2013-06-17 LU LU92218C patent/LU92218I2/fr unknown
- 2013-06-19 HU HUS1300027C patent/HUS1300027I1/hu unknown
- 2013-06-19 FR FR13C0032C patent/FR13C0032I2/fr active Active
- 2013-06-19 CY CY2013023C patent/CY2013023I1/el unknown
- 2013-06-20 BE BE2013C040C patent/BE2013C040I2/fr unknown
- 2013-06-20 NL NL300599C patent/NL300599I2/nl unknown
2015
- 2015-01-19 NO NO2015001C patent/NO2015001I2/no unknown

Also Published As

Publication number	Publication date
LU92218I2 (fr)	2014-01-07
NO20052691L (no)	2005-07-15
NO2015001I1 (no)	2015-01-19
ZA200503510B (en)	2006-12-27
NO20052691D0 (no)	2005-06-06
MXPA05004925A (es)	2005-08-18
DE60336334D1 (de)	2011-04-21
US20110230530A1 (en)	2011-09-22
BR0316080A (pt)	2005-09-27
US20060115540A1 (en)	2006-06-01
EP1559427A4 (en)	2007-05-30
CY1111399T1 (el)	2015-08-05
IL168121A (en)	2011-12-29
CY2013023I2 (el)	2015-10-07
CN100406011C (zh)	2008-07-30
BE2013C040I2 (da)	2023-03-07
AU2003284700B2 (en)	2009-05-28
FR13C0032I2 (fr)	2014-03-07
AU2003284700A1 (en)	2004-06-07
PL211687B1 (pl)	2012-06-29
USRE44872E1 (en)	2014-04-29
NO334948B1 (no)	2014-08-04
SI1559427T1 (sl)	2011-06-30
NO2015001I2 (no)	2015-01-26
NZ539577A (en)	2007-06-29
JPWO2004041276A1 (ja)	2006-03-02
CN1711085A (zh)	2005-12-21
KR100967070B1 (ko)	2010-07-01
CA2503570C (en)	2011-04-19
US20090093529A1 (en)	2009-04-09
JP3815496B2 (ja)	2006-08-30
ES2360353T3 (es)	2011-06-03
PT1559427E (pt)	2011-05-27
RU2005117367A (ru)	2006-01-20
KR20050072809A (ko)	2005-07-12
US7750029B2 (en)	2010-07-06
LU92218I9 (da)	2019-01-17
NL300599I2 (da)	2017-01-03
PL376771A1 (pl)	2006-01-09
FR13C0032I1 (da)	2013-08-09
RU2321401C2 (ru)	2008-04-10
CA2503570A1 (en)	2004-05-21
US8835474B2 (en)	2014-09-16
WO2004041276A1 (ja)	2004-05-21
EP1559427B1 (en)	2011-03-09
EP1559427A1 (en)	2005-08-03
CY2013023I1 (el)	2015-10-07
ATE500827T1 (de)	2011-03-15
HUS1300027I1 (hu)	2016-08-29

Publication	Publication Date	Title
DK1559427T3 (da)	2011-04-26	Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel
HRP20020182B1 (en)	2007-08-31	Benzamide formulation with histone deacetylase inhibitor activity
DE60128258D1 (de)	2007-06-14	Indanylderivate zur Behandlung von Atemwegserkrankungen
NO20052817D0 (no)	2005-06-10	Anvendelse av EDG2-reseptor i en dyremodell for hjertesvikt
DE69017654D1 (de)	1995-04-13	Äusserlich anzuwendende analgetische lotion und verfahren zur herstellung.
NO20044974L (no)	2004-11-16	Imidazo [1,2-a]pyrazin-8-ylaminer, fremgangsmater for fremstilling og anvendelse derav
WO2002085861A8 (en)	2003-07-17	Imidazolidine compounds and their use as cxcr3 antagonists
DK1369419T3 (da)	2007-09-24	N-phenylarylsulfonamidforbindelse, lægemiddel indeholdende forbindelsen som en aktiv bestanddel, mellemprodukt for forbindelsen og fremgangmåder til fremstilling heraf
RU2006118786A (ru)	2007-12-10	Твердый препарат
CA2403352C (en)	2009-05-05	Use of comt inhibitors as analgesics
EP1152002A4 (en)	2002-04-17	PYRROL DERIVATIVES AND CELL DEATH INHIBITORS
RU2005135647A (ru)	2006-06-10	Комбинации, включающие пароксетин и {1-(r)-(3.5-бис-трифтор-2-метилфенил) этилметиламид}-2-(s)-(4-фтор-2-метилфенил) пиперазин-1-карбоновой кислоты, для лечения депрессии и/или тревоги
DE60007548D1 (de)	2004-02-05	Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
FR2490490A1 (fr)	1982-03-26	Agent antihypertenseur comprenant un n-(mercaptoacyl)amino-acide et du probenecide
ITTO20020102A1 (it)	2003-08-06	Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili.
LV11524A (lv)	1996-10-20	Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
NO20031030D0 (no)	2003-03-05	Nye krystaller av N-hydroksy-2(S)-metyl-5-etoksymetoksy-4(S)- [N-(4-fenoksyfenylkarbonyl)amino]pentanamid, fremgangsmåte for deresfremstilling og medisinerinneholdende krystallene som den aktive bestanddel
EP1466909A4 (en)	2005-12-07	HALOGENBENZYLAMINOPROPIONSÄUREDERIVATE
ITMI20000376A0 (it)	2000-02-29	Allomorfo del cloridrato dell'isomero z di derivato di alchilamminofurano procedimento per la sua produzione e composizione farmaceutica che
KR927003530A (ko)	1992-12-18	이온삼투요법용 제약 제제의 제조에 있어서의 국소 마취제의 용도
ITMI20030064A1 (it)	2004-07-18	Uso dei derivati dell'acido idrossamico per la preparazione
TH63279A (th)	2004-08-09	สารประกอบที่ปรับฤทธิ์ ppar
TH77897A (th)	2006-06-05	สารเชิงการบำบัด
RU2004108902A (ru)	2005-10-27	Способ лечения отморожений iii-iv степени